Lilly’s EBGLYSS shows improvement in Phase IIIb study for atopic dermatitis
The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.
28 October 2024
28 October 2024
The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.